B-type natriuretic peptide in heart failure: Diagnostic, prognostic, and therapeutic use

Critical Pathways in Cardiology

Volumn 4, Issue 1, 2005, Pages 10-20

  Mehra, Mandeep R ^a   Maisel, Alan ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acute decompensated heart failure; BNP; Heart failure; Natriuretic peptides; Nesiritide

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; MILRINONE; NESIRITIDE; NEUROHORMONE; NITROPRUSSIDE SODIUM; PLACEBO; VASOACTIVE AGENT;

ABDOMINAL PAIN; ARTERY DILATATION; ARTICLE; CARDIOVASCULAR RISK; DIFFERENTIAL DIAGNOSIS; DIURESIS; DYSPNEA; ECONOMIC ASPECT; HEADACHE; HEART FAILURE; HEART HEMODYNAMICS; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LONG TERM CARE; LUNG DISEASE; LUNG WEDGE PRESSURE; NATRIURESIS; NAUSEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; UREMIA; VEIN DILATATION;

EID: 14844344008     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hpc.0000155219.26524.19     Document Type: Article

References (55)

1. American Heart Association and American Stroke Association. Heart Disease and Stroke Statistics. 2005 Update.
2. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99-104.
3. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000;23(suppl III):III-6-III-10.
4. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
5. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug-partners in the diagnosis of congestive heart failure. Congest Heart Fail. 2004;10(suppl 1):3-27.
6. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation. 2003;108:2950-2953.
7. Abassi Z, Karram T, Ellaham S, et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004;102:223-241.
8. Nakagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280-1287.
9. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825-832.
10. Hunt PJ, Yandle TG, Nicholls MG, et al. The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma. Biochem Biophys Res Commun. 1995;214:1175-1183.
11. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med. 2003;4:72-80.
12. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781-1787.
13. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10(suppl 3):1-30.
14. Maisel A. B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail. 2001;7:183-193.
15. Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl. 1999;230:132-142.
16. Belenky A, Smith A, Zhang B, et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta. 2004;340:163-172.
17. Hammerer-Lercher A, Neubauer E, Muller S, et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001;310:193-197.
18. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735-1743.
19. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-2397.
20. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular function, natriuretic peptides, and mortality in an urban population. Heart. 2001;86:21-26.
21. Zellner CC, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol. 1999;276:H1049-H1057.
22. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221-1227.
23. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37-44.
24. Aronson D, et al. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002;90:435-438.
25. Grantham JA, Borgeson DD, Bumett JC Jr. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol. 1997;272:R1077-R1083.
26. Yasue H, Yoshirnura M. Natriuretic peptides in the treatment of heart failure. J Card Fail. 1996;2:S277-S285.
27. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
28. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
29. Yoshimura M, Yasue H, Ogawa H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol. 2001;79:730-735.
30. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J. 1998;135:914-923.
31. Shima M, Seino Y, Torikai S, et al. Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments. Life Sci. 1988;43:357-363.
32. Smith MW, Espiner EA, Yandle TG, et al. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol. 2000;167:239-246.
33. NDA 20-920, Volume 37, Page 37, Clinical Pharmacology of Human B-Type Natriuretic Peptide.
34. Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93:237-240.
35. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328-1333.
36. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
37. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
38. Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J. 2002;144:834-839.
39. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
40. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
41. Bhalla MA, Chiang A, Epshteyn VA, et al. Prognostic role of b-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2004;44:1047-1052.
42. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail. 2004;6:355-358.
43. Wu AH, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol. 2004;93:1562-1563.
44. Kazanegra R, Chen V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21-29.
45. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
46. Fitzgerald RL, Cremo R, Gardetto N, et al. The effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J. In press.
47. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002;3(suppl 4):S10-S17.
48. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590-1595.
49. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
50. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571-579.
51. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422.
52. Peacock F, Emerman CL, Costanzo MR, et al. Early initiation of intravenous vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database [Abstract]. Ann Emerg Med. 2003;42:S26.
53. The ADHERE database. Data on file. 2004.
54. Natrecor [package insert]. Fremont, CA: Scios Inc; 2004.
55. Keating MA, Goa KL. Nesiritide: A review of its use in acute decompensated heart failure. Drugs. 2003;63:47-70.